Enter Note Done
Go to previous page in this tab
Event
  • Informational Session
  • Bookmark Icon
  • Navigating PFAS in Medical Device Safety: A Cross-Disciplinary Scientific Evaluation of Materials, Biological Safety, Product Stewardship, and Emerging Toxicological Approaches
  • Schedule
    Notes
  • Stars at Night Ballroom B2‚ Convention Center
    Set Timezone


Chair: Xiaoling Dai, Abbott
Co-Chair: Catherine Christensen, Solventum

Primary Endorser: Medical Device and Combination Product Specialty Section


Endorser(s): Regulatory and Safety Evaluation Specialty Section


Endorser(s): American Association of Chinese in Toxicology Special Interest Group


Per- and polyfluoroalkyl substances (PFAS) present a complex and evolving challenge across regulated industries, including medical devices, where device performance and functionality, patient safety, and regulatory expectations must be carefully balanced. Coordinated efforts integrate biocompatibility, product stewardship, toxicology, material engineering, and evolving regulatory expectations with advancing scientific methodologies. This informational session will examine medical device related PFAS consideration within a comprehensive, risk based safety framework, emphasizing practical implementation and state of the art scientific advancement relevant to medical device research and development.
The first presentation will start with an overview of PFAS fluoropolymers used in medical devices, review the historical context of fluoropolymer use, their critical functional properties, and their role in life saving devices. Distinctions between HMW fluoropolymers and low molecular weight PFAS will be discussed, along with current global regulatory trends, including evolving EU REACH policies, U.S. EPA regulations, U.S. FDA perspectives on their use in medical devices, and emerging regulatory compliance risks.
The second presentation will provide an industry perspective on PFAS product stewardship, highlighting strategies for identifying PFAS across medical device materials and manufacturing processes, assessing essential versus non essential uses, and proactively evaluating alternatives while maintaining device performance, regulatory compliance, innovation, and patient safety.
The third presentation will address practical challenges in biological safety risk assessment, including case studies related to the selection of alternative materials and optimized manufacturing process, exposure characterization, and chemical safety risk and toxicity related characterization for medical device materials and extractables and leachables.
The final presentation will highlight recent advances in regulatory science tools developed by FDA CDRH Office of Science and Engineering Laboratories as well as collaborative efforts with industry stakeholders. Those tools leverage the totality weight of evidence to support hazard characterization and safety assessment on PFAS materials used in medical devices. It further examines current knowledge gaps and discuss the integration of multiple lines of evidence to inform the development of regulatory guidance and international ISO 10993 standards.
By bringing together multidisciplinary perspectives from industry, academia, consulting, and regulatory science tools, the session aims to foster dialogue to harmonize scientific evidence and address relevant uncertainties and data gaps to strengthen informed regulatory decision making, risk mitigation, and innovation in the evolving PFAS landscape for the biological safety of medical devices. Collectively, this session will highlight toxicology related advances in PFAS identification, prioritization, safety related strategies, and regulations in medical device innovation.

Session and Activity Type
Presentations